scholarly journals Drug-Induced Interstitial Lung Disease: A Systematic Review

2018 ◽  
Vol 7 (10) ◽  
pp. 356 ◽  
Author(s):  
Sarah Skeoch ◽  
Nicholas Weatherley ◽  
Andrew Swift ◽  
Alexander Oldroyd ◽  
Christopher Johns ◽  
...  
Keyword(s):  
Systematic Review ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Prospective Studies ◽  
Meta Analysis ◽  
Incidence Rates ◽  
Drug Induced ◽  
Common Causes ◽  
Review Question ◽  
Radiological Pattern

Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing authorisation of such agents. Methods: In this PRISMA-compliant systematic review, we aimed to evaluate and synthesise the current literature on DIILD. Results: Following a quality assessment, 156 full-text papers describing more than 6000 DIILD cases were included in the review. However, the majority of the papers were of low or very low quality in relation to the review question (78%). Thus, it was not possible to perform a meta-analysis, and descriptive review was undertaken instead. DIILD incidence rates varied between 4.1 and 12.4 cases/million/year. DIILD accounted for 3–5% of prevalent ILD cases. Cancer drugs, followed by rheumatology drugs, amiodarone and antibiotics, were the most common causes of DIILD. The radiopathological phenotype of DIILD varied between and within agents, and no typical radiological pattern specific to DIILD was identified. Mortality rates of over 50% were reported in some studies. Severity at presentation was the most reliable predictor of mortality. Glucocorticoids (GCs) were commonly used to treat DIILD, but no prospective studies examined their effect on outcome. Conclusions: Overall high-quality evidence in DIILD is lacking, and the current review will inform larger prospective studies to investigate the diagnosis and management of DIILD.

scholarly journals Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis

2021 ◽  
Vol 18 ◽  
pp. 147997312199456
Author(s):  
Peining Zhou ◽  
Jing Ma ◽  
Guangfa Wang
Keyword(s):  
Systematic Review ◽  
Interstitial Lung Disease ◽  
Confidence Interval ◽  
Lung Disease ◽  
Mortality Risk ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
Anca Associated Vasculitis ◽  
Retrospective Cohort Studies

Several retrospectivee described the association of interstitial lung disease (ILD) and ANCA-associated vasculitis (AAV). However, the relationship between the ILD and mortality in AAV patients have not been established so far. This study aims to estimate the relevance of AAV-associated-ILD (AAV-ILD) and mortality risk by conducting a systematic review and meta-analysis.A comprehensive systematic review was conducted in accordance with the guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses). PubMed, Embase.com and the Cochrane Library (Wiley) were searched for original observational studies. Summary estimates were derived with a random-effects model and reported as risk ratio (RR), tested for publication bias and heterogeneity. Ten retrospective cohort studies were included, comprising 526 AAV-ILD patients enrolled from 1974 to 2018. Meta-analysis yielded a pooled RR of 2.90 (95% confidence interval 1.77–4.74) for death among those with AAV-ILD compared to control group. UIP pattern was associated with an even poorer prognosis in comparison to non-UIP pattern (RR 4.36, 95% confidence interval 1.14–16.78). Sensitivity analysis suggested that the meta-RR result was not skewed by a single dominant study. ILD might be associated with a higher mortality risk in AAV patients.

Systematic review: In vivo imaging in animal models relevant to drug-induced Interstitial lung disease (DIILD)

2018 ◽  
Author(s):  
Irma Mahmutovic Persson ◽  
Karin Von Wachenfeldt ◽  
Kashmira Pindoria ◽  
Juan A. Delgado-San Martin ◽  
Simon Campbell ◽  
...  
Keyword(s):  
Systematic Review ◽  
Interstitial Lung Disease ◽  
Animal Models ◽  
Lung Disease ◽  
In Vivo Imaging ◽  
Drug Induced

scholarly journals VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature

2019 ◽  
Vol 25 (2) ◽  
pp. 218-222 ◽  
Author(s):  
Yu Jun Wong ◽  
Si Yuan Chew ◽  
John Chen Hsiang ◽  
Prem Harichander Thurairajah ◽  
Rahul Kumar ◽  
...  
Keyword(s):  
Systematic Review ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Case Series ◽  
Review Of Literature ◽  
Drug Induced ◽  
Disease Case

scholarly journals Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0155381 ◽  
Author(s):  
Li Zhang ◽  
Guoqin Wu ◽  
Di Gao ◽  
Guijian Liu ◽  
Lin Pan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Meta Analysis ◽  
Factors Associated

scholarly journals Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis

2019 ◽  
Vol 18 (2) ◽  
pp. 113-122 ◽  
Author(s):  
Thomas Barba ◽  
Romain Fort ◽  
Vincent Cottin ◽  
Steeve Provencher ◽  
Isabelle Durieu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Meta Analysis ◽  
Inflammatory Myositis ◽  
Idiopathic Inflammatory Myositis

scholarly journals Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease

BMJ Open ◽  
2018 ◽  
Vol 8 (12) ◽  
pp. e023998 ◽  
Author(s):  
Hiroyuki Kamiya ◽  
Ogee Mer Panlaqui ◽  
Shinyu Izumi ◽  
Takashi Sozu
Keyword(s):  
Systematic Review ◽  
Prognostic Factors ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Evaluation System ◽  
Meta Analysis ◽  
Inflammatory Myopathy ◽  
Idiopathic Inflammatory Myopathy ◽  
All Cause Mortality ◽  
Radiological Abnormality

ObjectiveTo clarify prognostic factors for idiopathic inflammatory myopathy (IIM)-associated interstitial lung disease (ILD).DesignSystematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation system.Data sourcesMedline, EMBASE and Science Citation Index Expanded were searched through 9 August 2018.Eligibility criteria for selecting studiesThe review includes primary studies addressing all-cause mortality of IIM-associated ILD. Potential prognostic factors were any clinical information related to the outcome.Data extraction and synthesisTwo reviewers extracted relevant data independently and assessed risk of bias using the Quality in Prognostic Studies tool. Meta-analysis was conducted using a random effects model and if inappropriate the results were reported qualitatively. Prognostic factors were determined based on statistically significant results derived from multivariate analysis.ResultsOf a total of 5892 articles returned, 32 were deemed eligible for analysis and cumulatively, these studies reported 28 potential prognostic factors for all-cause mortality. Each study was subject to certain methodological constraints. The four prognostic factors, which demonstrated statistically significant results on both univariate and multivariate analyses, were as follows: age (MD 5.90, 3.17–8.63/HR 1.06, 1.02–1.10 and 2.31, 1.06–5.06), acute/subacute interstitial pneumonia (A/SIP) (OR 4.85, 2.81–8.37/HR 4.23, 1.69–12.09 and 5.17, 1.94–13.49), percentage of predicted forced vital capacity (%FVC) (OR 0.96, 0.95–0.98/HR 0.96, 0.93–0.99) and anti-Jo-1 antibody (OR 0.35, 0.18–0.71/HR 0.004, 0.00003–0.54) (univariate/multivariate, 95% CI). Other prognostic factors included ground glass opacity/attenuation (GGO/GGA) and extent of radiological abnormality. The quality of the presented evidence was rated as either low or very low.ConclusionsOlder age, A/SIP, lower value of %FVC, GGO/GGA and extent of radiological abnormality were demonstrated to predict poor prognosis for IIM-associated ILD while a positive test for anti-Jo-1 antibody indicated better prognosis. However, given the weak evidence they should be interpreted with caution.Trial registration numberCRD42016036999.

Sign in / Sign up

Export Citation Format

Share Document